Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)

Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)

Conclusions IGHy administered at a frequency similar to IGIV over 3 years was effective in maintaining low infection rates in patients with PI, and the AE profile was comparable to that previously reported for IGSC at infusion volumes and rates equivalent to IGIV.

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology Vol. 135; no. 2; p. AB96
Main Authors: Wasserman, Richard L., MD, PhD, FAAAAI, Stein, Mark R., MD, FAAAAI, Melamed, Isaac, MD, Kobrynski, Lisa J., MD, MPH, FAAAAI, Gupta, Sudhir, MD, Puck, Jennifer M., MD, Rubinstein, Arye, MD, Engl, Werner, McCoy, Barbara, Leibl, Heinz, PhD, Yel, Leman, MD, FAAAAI
Format: Journal Article
Language:English
Published: St. Louis Elsevier Limited 01-02-2015
Subjects:
Allergy and Immunology
Infections
Medical research
Patients
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conclusions IGHy administered at a frequency similar to IGIV over 3 years was effective in maintaining low infection rates in patients with PI, and the AE profile was comparable to that previously reported for IGSC at infusion volumes and rates equivalent to IGIV.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2014.12.1247